markets2017-05-26
Merck & Co has bought itself an exclusive global licence from Teijin Pharma to develop, manufacture and commercialise an investigational preclinical antibody candidate targeting a protein called tau. Source: PharmaTimes....Read more
markets2017-05-26
Patients report more side effects when they know they are taking a statin than when don’t, according to findings of a recent study led by researchers at Imperial College London, funded by Pfizer, and published in The Lancet. Source: PharmaTimes....Read more
markets2017-05-26
Pfizer’s biosimilar of Amgen’s epoetin alfa (Epogen/Procrit) has won backing in the US for approval across all proposed indications. Source: PharmaTimes....Read more
markets2017-05-26
US regulators will undertake a speedy review of Bristol-Myers Squibb’s application to expand use of its immunotherapy Opdivo to include to include certain patients with liver cancer. Source: PharmaTimes....Read more
markets2017-05-25
The UK has the strongest and most robust clinical pipeline in Europe, with the number of drug products in development higher in the UK than anywhere else in the region, according to a new report by the BioIndustry Association. Source: PharmaTimes....Read more
markets2017-05-25
The European Medicines Agency has cleared use of Bial and Eisai’s sodium channel blocker Zebinix for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy, widening its treatment scope in the region. Source: PharmaTimes....Read more
markets2017-05-24
GW Pharmaceuticals is on the brink of filing its cannabis-derived therapy Epidiolex in the US as another late-stage study highlights the drug’s efficacy in treating Dravet Syndrome, a rare and severe type of epilepsy. Source: PharmaTimes....Read more
markets2017-05-24
Ulster University is streaming £2 million into a new health technology hub which aims to support the rapid research and development of pioneering healthcare tech. Source: PharmaTimes....Read more
markets2017-05-24
Cost regulators for the NHS in England and Wales are recommending UCB's Cimzia and Novartis' Cosentyx as treatment options for adults with active psoriatic arthritis. Source: PharmaTimes....Read more
markets2017-05-24
Biogen’s Fampyra has been granted a standard approval by European regulators on the back of late-stage data supporting its use to improve walking in patients with multiple sclerosis. Source: PharmaTimes....Read more
markets2017-05-24
The UK’s Competition and Markets Authority (CMA) has provisionally found that a discount scheme operated by Merck & Co. - known as MSD outside the U.S. - for its biologic Remicade may have restricted competition from cheaper biosimilar versions of the drug entering the market. Source: Pharm....Read more
markets2017-05-24
The US Food and Drug Administration has cleared use of Merck & Co’s immunotherapy Keytruda to treat cancer patients identified as having a biomarker called microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Source: PharmaTimes....Read more
Load More Content
